Corvus Pharmaceuticals rakes in $75 mln Series B

Burlingame, California-based Corvus Pharmaceuticals, a biopharmaceutical company focused on treating cancer, has raised $75 million in Series B funding. Rock Springs Capital Management led the round with participation from other investors that included Fidelity Management and Research Company, Blackrock, Roche Venture Fund, Cormorant Asset Management, venBio Select, Cowen Private Investments, Orbimed, Novo Ventures and Adams Street Partners. Cowen and Company advised Corvus on the transaction. PRESS RELEASE BURLINGAME, Calif.–(BUSINESS WIRE)–Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, today announced that it closed a $75 million Series B financing. The transaction was led by Rock Springs Capital Management and included other leading healthcare investors such as Fidelity Management and Research Company, Blackrock, funds, accounts managed by T. Rowe Price, Jennison Associates (on behalf of certain clients), Roche Venture Fund, Cormorant Asset Management, Sphera Funds Management, venBio Select and Cowen Private Investments. Founding investors, Orbimed, Novo Ventures and Adams Street Partners also participated in the transaction. Cowen and Company served as an advisor to Corvus. “We are delighted to attract this pre-eminent group of investors, which provides the capital for Corvus to advance the development of multiple product candidates, including an expansion cohort designed Phase 1B trial that will evaluate our novel oral checkpoint inhibitor alone and in combination with another checkpoint inhibitor in several different types of cancer,” said Richard A. Miller, M.D., Chief Executive Officer of Corvus Pharmaceuticals. The proceeds will be used to expand the company’s research and development programs of multiple small molecule and antibody agents in immuno-oncology, including the initiation of a multicenter Phase 1B trial, which is expected to begin in the first quarter of 2016. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. A Phase 1B clinical trial evaluating its oral small molecule checkpoint inhibitor is scheduled to begin in the first quarter of 2016. For more information, visit www.corvuspharma.com.

Excerpt from:
Corvus Pharmaceuticals rakes in $75 mln Series B

Kraton to buy privately held Arizona Chemical for $1.37 bln: Reuters

(Reuters) Kraton Performance Polymers Inc, a producer of rubber used in adhesives, coatings and personal care products, said it would buy privately held specialty chemicals producer Arizona Chemical Holdings Corp for $1.37 billion in cash. The deal is expected to add about $1.40 per share in profit in the first year of combined operations, Kraton said. Reuters reported on Friday, citing sources, that Kraton was in talks to acquire Arizona Chemical Company LLC, which is majority owned by private equity firm American Securities LLC. Kraton said on Monday that it expected pretax synergies of $65 million by 2018 and free cash flow of more than $450 million over the first three years of combined operations. The Houston-based company said it would finance the deal through debt facilities committed by Credit Suisse Securities (USA) LLC, Nomura Securities International Inc and Deutsche Bank Securities Inc. The deal is expected to close later this year or early next year, Kraton said. The company’s shares closed at $18.35 on Friday on the New York Stock Exchange.

See the original post here:
Kraton to buy privately held Arizona Chemical for $1.37 bln: Reuters

Ardian acquires additional stake in CLH Group

Ardian has increased its stake to 25 percent in CLH Group. No financial terms were disclosed. The seller was Repsol. Based in Spain, CLH Group is an oil products and storage company. PRESS RELEASE Madrid, September 25, 2015 – Ardian, the independent investment company, announces today the acquisition of an additional 10% equity stake in the CLH Group (Compañía Logística de Hidrocarburos), the Spanish oil products and storage company, from Repsol, the integrated global energy company. With this investment Ardian reinforces its position as the largest shareholder in the company, increasing its shareholding to 25%. Ardian first became a shareholder in CLH in 2011 with the acquisition of a 10% stake, before acquiring an additional 5% stake in 2013. This new investment in CLH is further evidence of Ardian’s long-term commitment to essential infrastructure projects in Europe. CLH is the owner and operator of the largest Spanish oil products and storage network, with more than 4,000km of pipeline and seven million m3 of storage capacity in Spain, including strategic national reserves. CLH recently acquired the GPSS (Government Pipeline and Storage System), the largest oil distribution network in the United Kingdom, with a pipeline network of 2,000 kilometers, which represents 50% of the UK’s total network. GPSS also has 16 storage facilities with more than one million m3 combined storage capacity. Mathias Burghardt, Member of the Executive Committee and Head of Infrastructure at Ardian, said: “This investment will provide certainty and stability to CLH, a critical infrastructure asset in Spain. Ardian Infrastructure will continue to support the company’s efforts in providing its clients with the most efficient and reliable logistics services in Europe while leading the industry in further innovation.” Juan Angoitia, Managing Director of Infrastructure at Ardian, added: “Following the opening of its Madrid office in September, Ardian continues to strengthen its presence in Spain, where the company sees great opportunities. Having concluded our three transactions in CLH with customers and industrial shareholders highlights our ability to secure deal flow thanks to our local presence and network and to share long term vision for strategic assets.” Over the last decade Ardian Infrastructure has built a significant presence in core energy and transport infrastructure across Europe, forging strong partnerships with leading infrastructure players such as Abertis, the international market leader in the management of toll roads, and AENA, the public airport operator in Spain and abroad. This has led to joint investments in major infrastructure assets, including SANEF, the toll road network in France, Trados 45, a toll road in Madrid, the Vallvidrera and Cadí Tunnels near Barcelona, and London Luton Airport. ABOUT ARDIAN Ardian, founded in 1996 and led by Dominique Senequier, is an independent investment company with assets of US$50bn managed or advised in Europe, North America and Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty and entrepreneurship. Ardian maintains a truly global network, with more than 380 employees working through eleven offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, Beijing, Singapore, Jersey, Luxembourg. The company offers its 355 investors a diversified choice of funds covering the full range of asset classes through Ardian Funds of Funds (comprising primary, early secondary and secondary activities), Ardian Private Debt, Ardian Direct funds (comprising Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth and Ardian Co-Investment), Ardian Infrastructure, Ardian Real Estate and customized mandate solutions with Ardian Mandates.

Continued here:
Ardian acquires additional stake in CLH Group

Joylux pulls in $3 mln

Seattle-based consumer health and wellness company Joylux has secured $3 million in seed funding. The investors were not named. Also, Joylux has appointed Steve Traplin as its chief revenue officer. Previously, Traplin worked at We-Vibe. PRESS RELEASE Seattle, WA (September 22, 2015) –Joylux, Inc. announces it has closed on $3 million in seed funding from a team of private investors to develop therapeutic LED products to capitalize on the rapidly growing, billion-dollar home-use device market. The company’s inaugural product, vSculpt— launching winter 2015—is the first home-use medical device of its kind to address pelvic floor disorders affecting millions of women. “I’m gratified by the enthusiastic response we’ve received from investors who share our excitement for innovative devices that go beyond beauty and focus on women’s personal health and wellness,” says Joylux’s Founder and Chief Executive Officer Colette Courtion. Joylux also named its advisory board, which consists of co-founders Dr. Nicolas Loebel, CTO of Ondine Biomedical; Dr. Roger Andersen, OB-GYN and Clinical/Regulatory Affairs for Ondine Biomedical; Ken Pilcher, co-founder of the Clarisonic Skin Care System; and Adam Diamond, former CMO of Eddie Bauer and American Eagle. In addition, Steve Traplin, formerly of We-Vibe, will be joining the executive team as Chief Revenue Officer. “This dynamic group of industry experts have been influential in our research and development process. I look forward to their continued involvement as we introduce more ground-breaking LED-focused health and wellness products to our customers,” added Courtion. “Joylux is at the forefront of innovation in therapeutic LED products for home use. I’m proud to be an advisor to the company,” said Joylux, Inc. Advisor Ken Pilcher. “I believe the company will be delivering the next women’s health must-have device.” Joylux, Inc. Founders & Advisors: Colette Courtion, CEO A beauty product and device veteran, Courtion brings over 18 years of management, brand-building, product development, and marketing experience to Joylux. The former CEO/President of JeNu Biosciences (the first at-home anti-aging ultrasound system), CEO/Founder of Calidora Skin Clinic (a chain of premiere anti-aging skin clinics) and a marketing executive with Starbucks, Courtion and her products have been featured by many national news, broadcast and beauty publications including The Wall Street Journal, New York Times, FOX, EXTRA!, HSN, Vogue and InStyle. Dr. Nicolas Loebel, CTO Dr. Loebel is an expert in medical device research and development with in-depth experience in photochemistry, pharmaceutical development, fiber optics, laser and LED sources and integrated microelectronics. Currently President and CTO of Ondine Biomedical, Dr. Loebel has authored numerous publications and patents and has lectured globally on antimicrobial photodynamics. Dr. Roger Andersen, Chief Medical Officer/Regulatory/Clinical Testing Dr. Andersen has been a practicing gynecologist and surgeon for more than 25 years. He has vast experience in developing regulatory/quality and clinical programs for pharmaceutical and medical device companies. He currently serves as VP of Regulatory and Clinical Affairs for Ondine Biomedical. Dr. Andersen has authored many peer-reviewed publications and has worked extensively with the FDA, Health Canada, and Europe to obtain medical device regulatory approvals. Ken Pilcher Mr. Pilcher is the co-founder and lead inventor of the Clarisonic Skin Care System. He has over 30 years of product development experience including oral care products, medical electronics, and space-based data acquisition and avionics for the NASA Space Shuttle. Prior to Clarisonic, Mr. Pilcher was director of research and development for Optiva Corporation, maker of the Sonicare toothbrush. Adam Diamond Formerly the CMO at Eddie Bauer and American Eagle, Mr. Diamond brings to Joylux a vast amount of marketing and advertising experience, including 9 years as Senior Vice President of American Eagle Outfitters and 4 years as North and South American Brand Manager for Tiffany & Co. He is currently the Founder and CEO at Skoben Ventures, a venture and marketing consulting firm specializing in brand development, communications, and strategic positioning for early stage start-ups. Steve Traplin, CRO Mr. Traplin has over 40 years of VP sales, VP Marketing and CEO experience under his belt at multiple Canadian venture-backed software and consumer companies. He was formerly with We-Vibe, manufacturer of the most financially successful pleasure product ever launched. About Joylux, Inc. Joylux, Inc. is an innovative consumer health and wellness company creating transformational, powerful LED-based products that bring Joy to the lives of our customers. For more information, please visit us online at joyluxinc.com.

Read this article:
Joylux pulls in $3 mln

WalmartLabs buys VC-backed PunchTab

WalmartLabs has acquired PunchTab, the latter announced in a blog post on its site. No financial terms were disclosed. Based in Palo Alto, California, PunchTab is an omni-channel engagement and insights platform. Its backers included Mohr Davidow Ventures, The Social+Capital Partnership and Crunch Fund.

Read the original post:
WalmartLabs buys VC-backed PunchTab